And Enhance Igg2a Production in Vivo HLA-DM-Sufficient Antigen
Total Page:16
File Type:pdf, Size:1020Kb
Chemical Chaperones Enhance Superantigen and Conventional Antigen Presentation by HLA-DM-Deficient as well as HLA-DM-Sufficient Antigen-Presenting Cells This information is current as and Enhance IgG2a Production In Vivo of September 24, 2021. Birinder Ghumman, Edward M. Bertram and Tania H. Watts J Immunol 1998; 161:3262-3270; ; http://www.jimmunol.org/content/161/7/3262 Downloaded from References This article cites 44 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/161/7/3262.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Chemical Chaperones Enhance Superantigen and Conventional Antigen Presentation by HLA-DM-Deficient as well as HLA-DM-Sufficient Antigen-Presenting Cells and Enhance IgG2a Production In Vivo1 Birinder Ghumman, Edward M. Bertram, and Tania H. Watts2 Chemical chaperones, first defined in studies of mutant cystic fibrosis transmembrane conductance regulator proteins, are small molecules that act as stabilizers of proteins in their native state and have the ability in some cases to rescue protein-folding mutants within cells. HLA-DM is an MHC II-specific molecular chaperone that facilitates peptide loading onto MHC II proteins and also stabilizes empty MHC II molecules prior to their acquisition of antigenic peptides. APC that lack HLA-DM exhibit quantitative Downloaded from defects in protein Ag as well as superantigen presentation. Here we show that both the superantigen and protein presentation defect in MHC II-transfected, HLA-DM-deficient T2 cells can be partially overcome by treating the APC with the chemical chaperones glycerol, DMSO, or trimethylamine oxide. These chemical chaperones also enhance superantigen and conventional Ag presentation by wild-type APC. In vivo, glycerol was found to act as an adjuvant and resulted in enhanced IgG2a production to trinitrophenyl-keyhole limpet hemocyanin (TNP-KLH). In vitro, the enhancement of Ag presentation by chemical chaperones was found to take place at the level of the APC and took several hours to develop. Subcellular fractionation experiments show that http://www.jimmunol.org/ HLA-DM enhances presentation of peptides by dense endosome fractions whereas chemical chaperones enhance presentation by light membrane fractions (early endosome or plasma membrane). The mechanism by which these chemical chaperones augment Ag presentation is not defined, but flow cytometric analysis suggests that the enhancement may be due to a subtle effect on the stability of several different proteins at the cell surface. The Journal of Immunology, 1998, 161: 3262–3270. olecular chaperones bind to non-native conformations heterodimers on an invariant trimer (3). In the absence of invariant of proteins and stabilize them against irreversible ag- chain, MHC II is poorly expressed and largely remains aggregated gregation. Through controlled cycles of binding and in the ER (4–6). Thus, invariant chain is considered to be a spe- M by guest on September 24, 2021 release, molecular chaperones can facilitate the protein-folding cific molecular chaperone of the MHC II biosynthetic pathway. process. Once the native conformation of a protein is achieved, After assembly in the ER, the nonomeric abIi complex travels molecular chaperones no longer bind. Thus, molecular chaperones via the Golgi to an endocytic compartment where invariant chain are important in the retention of misfolded proteins as well as in is removed by proteolysis, leaving an MHC II a/b complex bound the protein-folding process itself (1). to a fragment of invariant chain, class II associate invariant chain The assembly of MHC class II molecules with their peptide peptides, CLIP (7, 8). In the endosome, abCLIP or larger precur- ligands involves a complex biosynthetic pathway in which molec- sors are acted upon by another specialized molecular chaperone, ular chaperones are involved at several stages (2). Shortly after HLA-DM. HLA-DM binds to MHC II molecules and thereby fa- synthesis in the endoplasmic reticulum (ER),3 individual MHC a- cilitates release of CLIP and other unstably bound peptides from and b-chains associate with the molecular chaperone calnexin. MHC II molecules (9–19). In addition, HLA-DM can stabilize Heterodimers of MHC II a- and b-chains are then assembled upon empty MHC II dimers and therefore maintain them in a state suit- an invariant chain (Ii) trimer that also contains bound calnexin. able for peptide binding, hence its definition as a molecular Calnexin dissociates from the Ii-MHC a/b complex upon comple- chaperone (20, 21). tion of formation of a nonameric complex consisting of three a/b APC that lack HLA-DM have a defect in peptide loading within APC (22). MHC II molecules in these cells remain associated with CLIP (23, 24). MHC II-CLIP complexes differ in kinetic stability Department of Immunology, University of Toronto, Toronto, Ontario, Canada from mature MHC II molecules as reflected in the instability of the Received for publication September 5, 1997. Accepted for publication May 27, 1998. CLIP-occupied MHC II dimer to SDS, at least for some MHC II The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance alleles (16, 22). HLA-DM-deficient APC present native protein with 18 U.S.C. Section 1734 solely to indicate this fact. Ags poorly (22, 25). However, HLA-DM deficiency does not im- 1 This work was supported by a grant from the National Cancer Institute of Canada pair surface expression of class II; therefore, DM-deficient cells (T.H.W.) with funds from the Terry Fox Foundation. T.H.W. is a senior research are capable of peptide presentation at the cell surface (22, 25). The scientist of the National Cancer Institute of Canada. affinity of CLIP for different MHC II alleles is quite variable, with 2 Address correspondence and reprint requests to Dr. Tania H. Watts, Department of k Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada. E-mail address: that for A being particularly low (26, 27). As a result, HLA-DM- k [email protected] deficient cells express A in the SDS-stable, CLIP-unoccupied 3 Abbreviations used in this paper: ER, endoplasmic reticulum; CLIP, class II asso- form, and the Ag presentation defect is not as severe as in DM- ciate invariant chain peptides; TMAO, trimethylamine oxide; CFTR, cystic fibrosis deficient cells expressing other MHC II alleles (28). However, in transmembrane conductance regulator protein; SEA, staphylococcal enterotoxin A; k PE, phycoerythrin; HB, homogenization buffer; HEL, hen egg lysozyme; KLH, key- the absence of HLA-DM, T cells specific for A and HEL46-61 hole limpet hemocyanin; TNP, trinitrophenyl. respond poorly to hen egg lysozyme (HEL) protein processed Copyright © 1998 by The American Association of Immunologists 0022-1767/98/$02.00 The Journal of Immunology 3263 within the APC (25) a defect that can be corrected, at least in part, tario, Canada) and 500 ng/ml Puromycin (Sigma, St. Louis, MO). SEA was by HLA-DM transfection (29). purchased from Toxin Technology (Sarasota, FL). Synthetic HEL46-61 In addition to an effect on protein Ag presentation, HLA-DM- was purchased from the Ontario Cancer Institute Biotechnology Facility (Toronto, Canada). The anti-Ak-producing hybridomas 10-2.16 and 11-5.2 deficient cells have a defect in presentation of the superantigen were obtained from the American Type Culture Collection. The anti-Aak- staphylococcal enterotoxin A (SEA) by murine MHC II molecules producing hybridoma 39J (41) was kindly provided by W. Wade (Dart- (30, 31). The staphylococcal enterotoxins are 25-kDa proteins that mouth Medical School, Hanover, NH). Abs were purified from hybridoma bind as intact proteins to MHC II proteins outside the peptide- culture supernatants using protein A or G Sepharose (Pharmacia, Piscat- away, NJ). For biotinylation, Abs were dialyzed overnight against 0.1 M binding groove and activate T cells by simultaneously binding to sodium bicarbonate, pH 8.5, followed by incubation with a 10-fold molar the MHC II on the APC and the TCR on T cells expressing par- excess of N-hydroxysuccinimidyl-D-biotin for2hatroom temperature. ticular TCR Vb segments (reviewed in Ref. 32). The binding of Free biotin was removed by dialysis against PBS. The superantigen SEA SEA to MHC II is peptide dependent, and the affinity of this toxin was biotinylated by the same method using a 10- or 20-fold molar excess for MHC II varies greatly with the peptide bound in the groove of N-hydroxysuccinimidyl-D-biotin over SEA. (33). Indeed, SEA does not appear to be presented efficiently by Treatment of APC with chemical chaperones and b CLIP-occupied A expressed on HLA-DM-deficient T2 cells (30). Ag/superantigen presentation assays Although not exclusively occupied with CLIP (28, 31), Ak mole- cules expressed on HLA-DM-deficient T2 cells also show a quan- The chemical chaperones DMSO, glycerol (BDH, Analar quality, distrib- uted by VWR Scientific, Mississauga, Canada), and TMAO (Sigma) were titative defect in their ability to bind and present SEA, a defect that diluted in serum-free culture medium and added to the cells at the con- is corrected by HLA-DM transfection (31).